Who is affected and how:

• Social media influencers and content creators: Directly targeted. They must follow accuracy standards for drug-related content, disclose/report covered payments, maintain records, and face civil penalties for false or misleading drug communications. Smaller creators will likely need to adopt compliance practices or rely on agencies/platforms for clarity.

• Telehealth providers and other health-care professionals using digital channels: Required to ensure drug-related communications are accurate and disclosed appropriately in telehealth settings, and to report payments where applicable. This adds compliance and documentation responsibilities for telehealth encounters.

• Drug manufacturers and sponsors: May be required to report or disclose transfers of value tied to influencer marketing or telehealth promotion and will face increased scrutiny of promotional pathways.

• Social media platforms and intermediaries: Although liability targets influencers and providers, platforms will likely be engaged for recordkeeping, cooperation with FDA surveillance, and may have to adapt policies or reporting support tools to meet agency guidance.

• FDA and federal regulators: Will gain new surveillance authority, staffing needs, and rulemaking tasks. The agency must produce guidance and reports within statutory deadlines and implement enforcement mechanisms.

• Consumers and patients: Intended to benefit from clearer, more accurate drug information online and in telehealth settings, reducing misleading promotion; could also see changes in the availability or format of influencer-driven health content.

Practical effects and tradeoffs:

• Compliance costs and administrative burden will rise for influencers, providers, and firms that fund or coordinate promotional activity; reporting systems, contracts, and disclosure practices will need updating.
• FDA will need to stand up surveillance and enforcement capacity; authorized funding helps but appropriations and hiring timelines will affect speed of implementation.
• Enforcement may chill some informal or anecdotal online communications about drugs, particularly where creators lack clarity about disclosure thresholds; careful FDA guidance will be critical.
• Cross-platform and cross-border enforcement challenges may limit practical reach unless platforms cooperate or implement features to support reporting and transparency.

Net effect: The provision aims to strengthen consumer protection against misleading drug promotion online and in telehealth, at the cost of added regulatory and recordkeeping burdens on influencers, providers, and industry; much depends on FDA guidance and resources for implementation.